Approach to the Patient with Type 2 Diabetes and Progressive Kidney Disease

被引:18
|
作者
Seaquist, Elizabeth R. [1 ]
Ibrahim, Hassan N. [2 ]
机构
[1] Univ Minnesota, Dept Med, Div Endocrinol & Diabet, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Med, Div Renal Dis & Hypertens, Minneapolis, MN 55455 USA
来源
关键词
STAGE RENAL-DISEASE; CORONARY-HEART-DISEASE; UNITED-STATES; PANCREAS TRANSPLANTATION; RISK; PHARMACOKINETICS; MORTALITY; MICROALBUMINURIA; COMPLICATIONS; HYPERTENSION;
D O I
10.1210/jc.2010-0504
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes is the leading cause of end-stage kidney disease in the United States. The management of patients with type 2 diabetes and progressive kidney disease requires a comprehensive approach that includes aggressive blood pressure control with agents that also lower urinary protein excretion and optimization of glucose and lipid control while remaining cognizant of the therapeutic limitations imparted by renal dysfunction. Clinicians must also address the comorbidities associated with renal failure such as anemia and secondary hyperparathyroidism. Diabetic nephropathy typically follows a slowly progressive course from albuminuria to azotemia. Consequently, optimal care includes planning for the management of impending renal failure long before the patient requires dialysis or transplantation. (J Clin Endocrinol Metab 95: 3103-3110, 2010)
引用
收藏
页码:3103 / 3110
页数:8
相关论文
共 50 条
  • [21] Soluble tumor necrosis factor receptor 2 is associated with progressive diabetic kidney disease in patients with type 2 diabetes mellitus
    Wu, Tsung-Hui
    Chang, Li-Hsin
    Chu, Chia-Huei
    Hwu, Chii-Min
    Chen, Harn-Shen
    Lin, Liang-Yu
    PLOS ONE, 2022, 17 (04):
  • [22] SECONDARY HYPERPARATHYROIDISM IN PATIENT WITH TYPE 2 DIABETES AND STAGES 3-4 CHRONIC KIDNEY DISEASE
    Egshatyan, Lilit V.
    Mokrysheva, Natalya G.
    DIABETES MELLITUS, 2018, 21 (02): : 128 - 134
  • [23] Circulating Fibroblast Growth Factor 21 Levels Predict Progressive Kidney Disease in Subjects With Type 2 Diabetes and Normoalbuminuria
    Lee, C. H.
    Hui, E. Y. L.
    Woo, Y. C.
    Yeung, C. Y.
    Chow, W. S.
    Yuen, M. M. A.
    Fong, C. H. Y.
    Xu, A.
    Lam, K. S. L.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (04): : 1368 - 1375
  • [24] Risk of progressive chronic kidney disease in individuals with early-onset type 2 diabetes: a prospective cohort study
    Liu, Jian-Jun
    Liu, Sylvia
    Gurung, Resham L.
    Ang, Keven
    Tang, Wern Ee
    Sum, Chee Fang
    Tavintharan, Subramaniam
    Lim, Su Chi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (01) : 115 - 121
  • [25] Diabetic kidney disease in type 1 diabetes: challenges and differences from type 2 diabetes
    Popovic, Djordje S.
    Patoulias, Dimitrios
    Gnudi, Luigi
    Mantzoros, Christos S.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 151
  • [26] Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes
    Moura-Neto, Jose A.
    Ronco, Claudio
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (11):
  • [27] Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease
    Mann, Johannes F. E.
    Fonseca, Vivian A.
    Poulter, Neil R.
    Raz, Itamar
    Idorn, Thomas
    Rasmussen, Soren
    von Scholten, Bernt Johan
    Mosenzon, Ofri
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (04): : 465 - 473
  • [28] Chronic kidney disease in patients with type 2 diabetes mellitus
    Kujawa-Szewieczek, Agata
    Piecha, Grzegorz
    Wiecek, Andrzej
    CLINICAL DIABETOLOGY, 2012, 1 (06): : 223 - 232
  • [29] Diversity of kidney disease in patients with type 2 diabetes mellitus
    Cordonnier, DJ
    Cantin, JF
    Pinel, N
    Zaoui, P
    Castro, PP
    Vanhille, P
    Verrier-Mine, O
    Halimi, S
    PRESSE MEDICALE, 2000, 29 (35): : 1957 - 1961
  • [30] Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes Reply
    Wanner, Christoph
    Inzucchi, Silvio E.
    Zinman, Bernard
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18): : 1801 - 1802